Pharvaris N.V.
PHVSNext catalyst
Deucrictibant
On-demand treatment of hereditary angioedema (HAE) attacks
Get an email about PHVS's next catalysts
Track Pharvaris (PHVS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout).See the timeline
4 upcoming, 1 past
PHVS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.82 | FQ end Sep/2026 | Call: tbd
Q3 2026 Portfolio Receipts grew 9% to $890M and Royalty Receipts grew 9% to $883M; full-year 2026 Portfolio Receipts guidance raised.
FDA PDUFA Date deucrictibant (immediate-release, 20 mg) (standard)
For On-demand treatment of hereditary angioedema (HAE) attacks. NDA filing. Extracted from SEC filing: EX-99.1
SourceDeucrictibant Phase 3 Est. Readout (CREAATE)
Primary completion for Deucrictibant trial (NCT07266805) in Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
SourcePhase 3 — deucrictibant XR
For Prophylaxis of hereditary angioedema (HAE) attacks. Pharvaris announced positive topline results from the CHAPTER-3 Phase 3 pivotal study of deucrictibant XR for HAE prophylaxis, with primary and all secondary endpoints met. Marketing authorization applications are planned to be submitted in H1 2027.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Deucrictibant
Hereditary Angioedema
Icatibant
Intradialytic Hypotension
Deucrictibant low dose
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Deucrictibant | Phase 3 | Hereditary Angioedema | - | - |
Icatibant | Phase 3 | Intradialytic Hypotension | - | - |
Deucrictibant low dose | Phase 2 | Hereditary Angioedema | - | - |
prophylaxis and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)
1 drug in this indication
hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Pharvaris N.V.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Pharvaris N.V.'s (PHVS) pipeline across Phase 3, Phase 2. Its lead program is Deucrictibant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharvaris N.V.'s next FDA catalyst?→
Pharvaris N.V.'s (PHVS) next tracked catalyst is a PDUFA date expected Apr 23, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHVS biotech catalysts?→
Add PHVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharvaris N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.